# Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy

> **NCT00268476** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Medical Research Council** · enrollment: 11992 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Celecoxib
- **DRUG:** Docetaxel
- **DRUG:** Prednisolone
- **DRUG:** ADT
- **DRUG:** Zoledronic Acid
- **DRUG:** Abiraterone
- **RADIATION:** Radiotherapy to the prostate
- **DRUG:** Enzalutamide
- **DRUG:** Metformin
- **DRUG:** Transdermal Oestradiol

## Key facts

- **NCT ID:** NCT00268476
- **Lead sponsor:** Medical Research Council
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2005-07-08
- **Primary completion:** 2026-03
- **Final completion:** 2030-12
- **Target enrollment:** 11992 (ACTUAL)
- **Last updated:** 2023-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00268476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00268476, "Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00268476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*